VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
AXGN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
AXGNAxoGen, Inc.
$56.95$3.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. AXGN
  4. Financial Ratios

AxoGen, Inc. (AXGN) Financial Ratios

Latest Ratios: P/E Ratio -109.8x · EV/EBITDA N/A · ROE -13.5%. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

AXGN Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$3.1B$1.5B$729M$293M$420M$386M$715M$702M$759M$943M$276M
Enterprise Value$3.1B$1.5B$771M$331M$472M$421M$720M$671M$734M$931M$271M
P/E Ratio →-109.77——————————
P/S Ratio11.476.693.891.843.033.036.376.589.0415.616.72
P/B Ratio20.3511.707.023.064.163.435.815.315.1637.4518.52
P/FCF187.70—66306.53————————
P/OCF3770.591856.19160.83————————

P/E links to full P/E history page with 30-year chart

AXGN EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—6.844.112.083.413.306.426.298.7515.416.58
EV / EBITDA—4474.73169.34————————
EV / EBIT———————————
EV / FCF——70045.80————————

AXGN Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin74.3%74.3%75.8%76.6%78.5%82.0%80.8%83.7%84.6%84.6%84.3%
Operating Margin-3.5%-3.5%-1.8%-13.5%-21.4%-20.0%-20.6%-29.4%-24.4%-13.2%-19.8%
Net Profit Margin-7.0%-7.0%-5.3%-13.7%-20.9%-21.2%-21.2%-27.3%-26.7%-17.3%-35.1%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE-13.5%-13.5%-10.0%-22.1%-27.1%-22.9%-18.6%-20.9%-26.0%-52.1%-124.7%
ROA-7.4%-7.4%-5.0%-11.1%-14.4%-13.2%-13.4%-18.5%-20.4%-19.9%-34.4%
ROIC-3.8%-3.8%-1.8%-11.2%-14.8%-13.8%-15.2%-21.0%-22.6%-52.9%-71.5%
ROCE-4.2%-4.2%-1.9%-12.7%-16.7%-14.0%-14.8%-22.4%-21.3%-19.8%-23.5%

AXGN Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity0.520.520.660.720.670.600.440.040.000.981.63
Debt / EBITDA196.60196.6015.10————————
Net Debt / Equity—0.250.400.400.520.310.04-0.23-0.16-0.47-0.38
Net Debt / EBITDA93.2693.269.04————————
Debt / FCF——3739.27————————
Interest Coverage-1.04-1.04-0.21-6.66-45.39-18.90-21.57-727.38-17.54-3.24-1.30

AXGN Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio5.115.113.242.894.135.236.366.4711.574.063.97
Quick Ratio3.313.312.162.143.334.545.815.8010.653.533.48
Cash Ratio1.511.511.091.022.053.464.554.628.942.662.71
Asset Turnover—1.020.920.810.710.610.560.690.521.030.89
Inventory Turnover1.371.371.371.611.571.371.721.251.081.271.18
Days Sales Outstanding—42.4146.9757.7258.4352.0457.2657.9666.6266.8471.50

AXGN Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield0.5%—0.0%————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$46M$44M$43M$42M$41M$40M$39M$37M$33M$31M

Key Metrics

Growth RegimeExpanding
ProfitabilityStrained
Balance SheetFortress
Cash FlowImproving
Top Statement Risk

Persistent operating losses

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Premium Multiples Price Growth Not Earnings

Based on reported figures, AXGN trades at 11.94 times trailing sales and 90.24 times forward earnings, a premium that leaves little room for execution slippage given its still-negative trailing margins.

The negative trailing P/E of -147.12 is not meaningful for valuation, so the market appears to be anchoring on revenue growth and the forward P/E of 90.24 rather than current earnings power. The 17.88 price-to-book ratio is elevated relative to a company whose equity is largely built from contributed capital, which suggests investors are paying for the clinical moat and BLA optionality rather than asset backing. Investors should monitor whether forward earnings estimates compress toward the peer group, since the current premium implies growth expectations that the recent margin history does not yet support.

Gross Margin Strength Masks Operating Drag

As reported in financial statements, AXGN's gross margin has held between 71.9% and 76.6% over ten quarters, yet operating margin remained negative in three of the last four quarters, indicating SG&A absorbs nearly all gross profit.

The stability of the 74-75% gross margin suggests the proprietary processing advantage is structurally intact even as volumes scale. However, the gap between gross and operating margin points to a heavy commercial cost base, consistent with a direct sales force still funding surgeon education. The most recent operating margin of 1.3% is a first sign of leverage, but a single quarter is insufficient to conclude that operating leverage is durable.

Debt Retired Leaves Negligible Coverage Risk

Based on AXGN's reported figures, the debt-to-equity ratio fell from 0.52 to 0.04 and the current ratio rose to 12.02 in 2026Q3, indicating that balance sheet leverage is no longer a meaningful constraint.

Total debt held near $20M after exceeding $68M through 2025, which substantially reduces refinancing and covenant exposure relative to the prior period. Interest coverage figures are distorted by near-zero or negative operating income in earlier quarters, so coverage cannot be reliably trended. The lower leverage appears to reflect capital inflows rather than operating cash generation, which warrants monitoring of how the balance sheet is deployed.

Cash Reserves Dwarf Short-Term Obligations

As reported in financial statements, AXGN's quick ratio of 10.67 in 2026Q3 reflects a cash position of $328.9M against liabilities of $54.2M, suggesting ample capacity to absorb a severe operating shortfall.

Liquidity appears strong enough that near-term solvency is not a plausible concern under the reported figures. The more relevant question is how quickly the cash balance is consumed if operating losses return, since the quick ratio is a point-in-time measure and does not reflect burn rate. Investors should weigh the liquidity cushion against the historical volatility of quarterly cash flow.

Working Capital Cycle Lengthens Despite Growth

Based on reported quarterly figures, AXGN's cash conversion cycle has moved between 91 and 273 days over ten quarters, with DPO volatility driving most of the swing rather than receivables collection.

DSO has held in a relatively tight 40 to 47 day range, indicating customer collection behavior is stable. The sharp variation in DPO and resulting CCC suggests payables timing, not operational efficiency, is the main driver of quarterly working capital movement. Investors should treat the most recent 122-day CCC cautiously until payables timing normalizes.

Peer Multiples Overstate Comparable Value

According to recent SEC filings, AXGN's 90.24 forward P/E and 17.88 price-to-book sit far above peers such as MDXG and XTNT, whose profitable margins make their multiples a more grounded reference point.

The bull case relies on the BLA transition and clinical moat translating into durable margin expansion, yet the current multiples already discount a large share of that outcome. Comparing AXGN to profitable peers like MiMedx and Xtant, which trade near 10 times earnings, highlights how much of the valuation rests on future rather than present cash generation. Investors should test whether the premium remains defensible if BLA timing slips or if operating leverage fails to appear in coming quarters.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open AXGN Terminal

AXGN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

AXGN — Frequently Asked Questions

Quick answers to the most common questions about buying AXGN stock.

What is AxoGen, Inc.'s P/E ratio?

AxoGen, Inc.'s current P/E ratio is -109.8x. The historical average is 3.5x.

What is AxoGen, Inc.'s ROE?

AxoGen, Inc.'s return on equity (ROE) is -13.5%. The historical average is -35.1%.

Is AXGN stock overvalued?

Based on historical data, AxoGen, Inc. is trading at a P/E of -109.8x. Compare with industry peers and growth rates for a complete picture.

What are AxoGen, Inc.'s profit margins?

AxoGen, Inc. has 74.3% gross margin and -3.5% operating margin.

How much debt does AxoGen, Inc. have?

AxoGen, Inc.'s Debt/EBITDA ratio is 196.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.